ITCI Stock Cash Flow Statements

Intra-Cellular Therapies Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Intra-Cellular Therapies Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-06-30

cash flows used in operating activities
net income	-16,885,000	-26,324,000	-16,220,000	-15,247,000	-28,579,000	-24,258,000	-42,784,000	-44,053,000	-44,026,000	-53,508,000	-86,603,000	-72,119,000	-85,733,937	-76,908,004	-68,743,782	-52,739,943	-60,699,178	-55,183,625	-63,712,258	-47,410,602	-40,582,851	-34,862,399	-37,441,165	-34,835,763	-40,748,036	-41,522,914	-37,376,383	-35,480,078	-30,208,712	-22,870,416	-17,760,704	-26,933,582	-27,485,039	-30,265,327	-30,834,453	-27,841,449	-28,834,516	-32,160,483	-21,511,318	-22,286,824	-15,199,130	-6,415,507	-4,533,539	-4,543,284	-8,040,810
adjustments to reconcile net income to net cash from operating activities:
depreciation	109,000	138,000	129,000	132,000	136,000	135,000	123,000	134,000	143,000	170,000	172,000	171,000	146,826	133,945	125,581	127,008	125,972	121,044	132,300	148,802		129,052	105,056	101,353		94,930	95,778	82,498		53,461	51,372	50,429		50,070	48,747	47,967		45,474	31,880	15,240		6,409	6,430	6,317	7,428
share-based compensation	16,333,000	17,489,000	16,370,000	13,843,000	14,856,000	14,311,000	13,226,000	10,439,000	11,159,000	11,751,000	11,998,000	8,105,000	9,377,619	9,530,269	8,616,705	6,778,436	4,763,047	6,900,719	6,947,134	5,504,297	5,939,279	4,806,768	4,987,424	5,055,217
stock issued for services	18,000	18,000	23,000	23,000	23,000	24,000	23,000	22,000	22,000	22,000	22,000	24,000	34,335	38,734	51,923	53,542	53,520	53,528	53,522	53,533	48,514	48,571	48,571	48,549
amortization of premiums and accretion of discounts on investment securities	-2,986,000	-1,847,000	-1,853,000	-2,343,000	-2,539,000	-2,191,000	-1,933,000	-1,737,000
changes in operating assets and liabilities:
accounts receivable	-20,892,000	106,000	-14,557,000	-17,139,000	-11,348,000	-6,706,000	-14,419,000	-6,356,000	-13,651,000	-14,562,000	-14,144,000	-12,676,000	-3,221,642	-1,746,538	-1,525,822	-2,897,409	-3,283,979	-5,127,349	-1,002,242	-1,351,013									6,309	55,626	6,265	26,139	-93,030	96,931	-98,240	30,660	-30,660	9,118	-5,803	48,288	72,811	94,824	-51,451	168,531	-85,027
inventory	-11,155,000	-1,374,000	-1,877,000	-499,000	-7,282,000	-1,091,000	-13,554,000	-4,421,000	-323,000	1,425,000	-17,129,000	55,000	218,809	-398,087	-189,455	-523,008	-4,109,247	-612,096	-943,918	-1,391,124
prepaid expenses and other assets	-17,036,000	-18,954,000	-7,801,000	-24,000,000	12,348,000	-16,388,000	10,140,000	-10,557,000	-1,063,000	-6,151,000	-3,608,000	-8,927,000	4,014,073	-7,268,245	-7,694,816	-258,929	-3,144,681	-6,364,640	3,150,271	-1,562,620	-2,555,046	-717,010	5,263,529	-526,089	-642,705	-1,368,845	249,944	-1,265,302	423,064	837,462	-2,383,537	243,811	18,312	-3,313	2,766,122	1,235,043	-6,492,239	7,078,812	-7,345,282	21,584	85,425	-881,022	221,251	108,247	43,245
accounts payable	15,736,000	-7,210,000	6,016,000	80,000	839,000	2,880,000	-708,000	-1,954,000	-3,824,000	3,470,000	-900,000	2,958,000	-3,339,394	-3,910,142	7,219,799	3,219,132	-3,067,323	3,096,161	-5,521,095	3,569,058	1,194,101	598,140	-2,941,650	-5,386,627	3,507,874	5,074,316	-4,659,980	3,865,311	1,765,884	2,632,403	-5,382,494	3,403,099	-1,662,804	1,527,885	1,930,294	326,367	927,862	-4,206,022	336,714	2,521,586	1,548,883	88,091	-1,726,988	-1,252,288	-632,030
accrued and other current liabilities	13,675,000	11,827,000	6,464,000	5,305,000	115,000	373,000	6,389,000	1,410,000	4,807,000
accrued customer programs	4,872,000	-7,435,000	7,999,000	16,799,000	17,555,000	3,908,000	1,818,000	4,271,000	5,675,000	3,463,000	10,514,076	4,924
accrued employee benefits	5,278,000	7,124,000	5,963,000	-10,955,000	1,916,000	3,825,000	4,967,000	-6,340,000	1,846,000
lease liabilities									-1,122,000	-2,000	-86,000	1,784,000	-53,018	-42,280	-42,062	-37,750	-27,261	-16,838	-16,625	-12,436
net cash from operating activities	-13,078,000	-26,525,000	542,000	-34,116,000	-2,061,000	-25,270,000	-36,802,000	-60,066,000	-39,193,000	-53,351,000	-94,793,000	-82,849,000	-73,184,535	-79,266,764	-59,325,234	-47,766,952	-68,242,719	-63,579,111	-47,024,797	-51,226,218	-35,055,916	-29,989,290	-27,308,710	-35,629,325	-29,161,536	-28,409,537	-33,614,041	-26,983,999	-24,792,734	-14,412,227	-24,888,290	-16,398,561	-28,450,347	-29,657,041	-13,499,416	-19,650,423	-35,055,633	-20,510,560	-31,004,682	-15,709,090	-6,206,335	-4,420,502	-5,197,476	-6,982,837	-8,627,808	-9,921
capex	427,000	-696,000	0	0	-1,000	0	0	0	28,000	-117,000	-123,000	-566,000	-1,242	-309,252	-15,244	0	-74,766	-169,909	0	-22,049	650,293	-221,112	-1,062,383	-67,193	-58,753	-16,023	-21,400	-295,092	-516,175	-104,166	-74,590	-28,498	0	-9,114	-35,977	-3,874	0	-108,887	-194,302	-520,396	-3,438	1	-5,205	-3,120	0	0
free cash flows	-12,651,000	-27,221,000	542,000	-34,116,000	-2,062,000	-25,270,000	-36,802,000	-60,066,000	-39,165,000	-53,468,000	-94,916,000	-83,415,000	-73,185,777	-79,576,016	-59,340,478	-47,766,952	-68,317,485	-63,749,020	-47,024,797	-51,248,267	-34,405,623	-30,210,402	-28,371,093	-35,696,518	-29,220,289	-28,425,560	-33,635,441	-27,279,091	-25,308,909	-14,516,393	-24,962,880	-16,427,059	-28,450,347	-29,666,155	-13,535,393	-19,654,297	-35,055,633	-20,619,447	-31,198,984	-16,229,486	-6,209,773	-4,420,501	-5,202,681	-6,985,957	-8,627,808	-9,921
cash flows from investing activities
purchases of investments	-257,602,000	-312,507,000	-88,524,000	-81,046,000	-104,464,000	-136,394,000	-65,954,000	-108,457,000	-115,502,000	-90,925,000	273,931,000	-826,713,000	-69,380,879	-35,295,188	-85,750,937	-34,147,683	-267,105,008	-203,924,385	-74,133,521	-210,466,633	-22,387,415	-32,555,011	-11,450,191	-14,327,684	-30,042,076	-57,457,564	-91,786,767	-91,870,300	-246,252,094	-68,640,217	-104,089,622	-101,944,891	-75,658,859	-137,869,225	-149,584,769	-32,644,315	-283,161,975	-137,475,341	-22,528,030	-71,142,903	-11,328,911	-19,828,139
maturities of investments	107,283,000	104,000,000	96,343,000	97,225,000	151,887,000	116,495,000	160,702,000	91,995,000	165,737,000	197,212,000	-236,579,000	505,244,000	120,891,427	99,375,715	134,559,982	150,416,932	90,844,111	60,877,534	66,375,890	57,503,736	59,474,130	73,012,648	67,234,361	59,136,544	44,247,047	85,737,637	120,761,737	155,442,867	94,883,966	105,906,683	135,038,024	93,103,865	77,335,984	190,848,353	177,668,019	42,216,191	32,261,264	92,000,386	24,169,154	4,958,644	9,884,518	1,994,790			0
purchases of property and equipment	427,000	-696,000			-1,000				28,000	-117,000	-123,000	-566,000	-1,242	-309,252	-15,244	0	-74,766	-169,909	0	-22,049	650,293	-221,112	-1,062,383	-67,193	-58,753	-16,023	-21,400	-295,092	-516,175	-104,166	-74,590	-28,498		-9,114	-35,977	-3,874		-108,887	-194,302	-520,396
net cash from investing activities	-149,892,000	-209,203,000	7,766,000	16,179,000	47,422,000	-20,167,000	94,748,000	-16,462,000	50,263,000	106,170,000	37,229,000	-322,035,000	51,509,306	63,771,275			-176,335,663	-143,216,760	-7,757,631	-152,984,946	37,737,008	40,236,525	54,721,787	44,741,667	14,146,218	28,264,050	28,953,570	63,277,475	-151,884,303	37,162,300	30,873,812	-8,869,524	1,677,126	52,970,014	28,047,273	9,568,002	-250,937,721	-45,583,842	1,446,822	-66,704,655	-1,447,831	-17,833,348	-47,449,991	-3,120	0
cash flows from financing activities
proceeds of public offerings																	0	375,843,802
proceeds from exercise of stock options	5,606,000	6,734,000	2,093,000	9,989,000	3,004,000	2,581,000	8,585,000	3,640,000	2,194,000	5,654,000	5,504,000	8,089,000	7,914,260	591,296	1,581,697	1,431,658	3,635,334			589,161		152,379	259,211	31,236
net cash from financing activities	5,606,000	6,734,000	545,179,000	9,989,000	3,004,000	2,581,000	8,585,000	3,640,000	2,187,000	5,654,000	5,504,000	441,814,000	7,914,260	591,296	1,581,697	1,431,658	3,635,334	378,494,407	4,479,841	277,567,347	2,792,775	152,379	259,211	31,236	185,864	155,398	6,130	337,796	162,126,632	0	6,599	224,185	-124,972,574	125,102,274	184,351	163,683	324,368	327,504,405	174,013	121,890,834	63,877	29,045	169,358	115,453,280	-293,280	5,900
net increase in cash, cash equivalents, and restricted cash	-157,364,000	-228,994,000	553,487,000	-7,948,000	48,365,000			-72,888,000	13,257,000	58,473,000	-52,060,000	36,930,000	-13,760,969	-14,904,193	-8,949,736	69,933,955	-240,943,048	171,698,536	-50,302,587	73,356,183
cash, cash equivalents, and restricted cash at beginning of period	0	0	0	149,517,000	0	0	0	150,365,000	0	0	0	93,765,000	0	0	0	61,445,933	0	0	0	107,636,849
cash, cash equivalents, and restricted cash at end of period	-157,364,000	-228,994,000	553,487,000	141,569,000	48,365,000	-42,856,000	66,531,000	77,477,000	13,257,000	58,473,000	-52,060,000	130,695,000	-13,760,969	-14,904,193	-8,949,736	131,379,888	-240,943,048	171,698,536	-50,302,587	180,993,032
cash paid for taxes	460,000	0																																					205,000	1,600	4,441	12,691	23,966	3,900	18,000
non-cash investing and financing activities
right of use assets under operating leases	0	0												8,647,089						97,234		0
the following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows:
cash and cash equivalents																129,979,888
restricted cash																1,400,000
total cash, cash equivalents and restricted cash																131,379,888
operating lease liabilities		-83,000	-114,000	-115,000		-92,000	-90,000	-924,000
proceeds from sale of common stock		0
supplemental cash flow information
proceeds of public offering										0	0	433,725,000								276,978,186
net decrease in cash, cash equivalents, and restricted cash
long term deferred tax asset																	0	0	0	264,609
amortization of premiums and discounts on investment securities										230,000	3,132,000	-4,079,000	-778,777	-1,593,187	-621,916	-1,085,948	-470,874	157,483	-36,647	-298,210		-224,829	-289,785	-356,798				-56,298
non-cash investing and financing activities right of use assets under operating leases																								219,703
accrued liabilities and other											6,758,000	-3,069,000	6,150,571	2,896,771	3,478,611	-402,083	1,617,285	-6,603,498	13,924,761	-8,740,512		232,417	2,959,310	270,833
right of use assets under operating vehicle fleet leases																	1,166,976	4,929,098
right of use assets under operating real estate leases
net cash from (used) in investing activities																116,269,249
non-cash investing and financing activitiesright of use assets under operating leases																9,179,216
deferred rent																									323,203	-35,480	-35,481	15,342	-24,845	-24,845	-24,846	93,323	304,813	304,813	288,249	373,642	715,962	360,515	360,516	160,112
proceeds from stock warrant
proceeds from exercise of stock options and issuances of restricted stock
operating activities
depreciation expense
amortization of premiums and discounts on investment activities
accrued liabilities and employee benefits
investing activities
financing activities
exercise of stock options
net increase in cash and cash equivalents																					5,473,867	10,399,614	27,672,288	9,143,578	-14,829,454	9,911	-4,654,341	36,631,272	-14,550,405	22,750,073			-151,745,795	148,415,247	14,732,208	-9,918,738	-285,668,986	261,410,003	-29,383,847	39,477,089	-7,590,289	-22,224,805	-52,478,109	108,467,323	-8,921,088
cash and cash equivalents at beginning of period																					0	0	0	54,947,502	0	0	0	37,790,114	0	0	0	48,642,225	0	0	0	47,159,303	0	0	0	61,325,044	0	0	0	35,150,924
cash and cash equivalents at end of period																					5,473,867	10,399,614	27,672,288	64,091,080	-14,829,454	9,911	-4,654,341	74,421,386	-14,550,405	22,750,073	5,992,121	23,598,325	-151,745,795	148,415,247	14,732,208	37,240,565	-285,668,986	261,410,003	-29,383,847	100,802,133	-7,590,289	-22,224,805	-52,478,109	143,618,247
proceeds from exercise of warrants
proceeds from line of credit
repayment of line of credit
proceeds from stock option exercises																											6,130	337,796	54,376	0	6,599	224,185	27,426	102,274	184,351	163,683	335,538	57,030	159,442	101,036	63,877	29,045			16,111
cash paid for interest																																									0	0	2,032	5,041	8,003
share-based compensation expense																										4,373,688	4,310,705	4,287,103	3,610,948	2,500,753	4,369,141	4,160,678	3,725,288	3,686,746	3,696,724	3,592,461	3,424,310	2,865,990	2,500,779	2,099,826	1,651,018	1,702,645	290,461	199,754	108,943
issuance of common stock for services																										48,543	47,709	47,699		47,703	47,730	47,726		62,729	62,655	45,675		45,646	45,656	45,682
net accretion of discounts and amortization of premiums of available-for-sale securities																										-310,460
accrued liabilities																										5,236,685	3,931,625	1,519,726		2,269,396	-3,984,078	2,367,851		-5,219,048	8,504,102	2,356,793		5,274,925	-5,611,362	1,514,091		750,256	554,607	-1,670,114
proceeds from warrants
cash flows from operating activities
issuance of stock for services
amortization of premiums on investment activities
payment of costs of public offerings																																					-11,170
amortization of premiums on investment securities																														86,230	172,861	141,965		101,473	136,384	182,418		175,465	193,538	151,325
proceeds from secured line of credit
net decrease in cash and cash equivalents																																-25,043,900
purchase of property and equipment																																									-3,438	1	-5,205	-3,120	0
proceeds from stock subscription																																													0
gross proceeds of public offering																																							0	122,083,012		0	0	116,191,285
payment of costs of public offering																																							14,571	-293,214		0	-10,533	-738,005
proceeds from stock subscriptions																																										0
deferred revenue																																													-416,682
proceeds from issuance of convertible promissory notes
gross proceeds of public offerings
gross proceeds of public and private offerings
payment of costs of public and private offerings
unrealized loss on investment securities
gross proceeds of private placement
payment of costs of private placement
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
accrued and other current liabilities and employee benefits
cash flows from operating activities:
net																																														-10,883
adjustment to reconcile net income to net cash from operating activities:
professional fees paid by related party on behalf of the company																																														3,400
increase in accounts payable and accrued expenses																																														-2,438
cash flows from financing activities:
increase in note payable - related party																																														5,900
proceeds from issuance of common stock
net increase in cash																																														-4,021
cash, beginning of period																																														4,070
cash, end of period																																														49
schedule of non-cash financing activities:
note 1 -
net cash (used in) operating activities
net cash (used in) investing activities

We provide you with 20 years of cash flow statements for Intra-Cellular Therapies stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Intra-Cellular Therapies stock. Explore the full financial landscape of Intra-Cellular Therapies stock with our expertly curated income statements.

The information provided in this report about Intra-Cellular Therapies stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.